NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, Price Target & More

Get Started

$17.34 +0.78 (+4.71 %)

(As of 05/23/2018 04:00 PM ET)

Previous Close$17.34

Today's Range$16.30 - $17.57

52-Week Range$5.00 - $51.90

Volume56,007 shs

Average Volume22,634 shs

Market Capitalization$45.14 million

P/E Ratio5.90

Dividend YieldN/A

Beta-0.57

About Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Metal mining

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:OPNT

CUSIPN/A

Webwww.opiant.com

Phone310-598-5410

Debt

Debt-to-Equity RatioN/A

Current Ratio2.43

Quick Ratio2.43

Price-To-Earnings

Trailing P/E Ratio5.90

Forward P/E Ratio-3.44

P/E GrowthN/A

Sales & Book Value

Annual Sales$18.45 million

Price / Sales2.43

Cash Flow$3.1642 per share

Price / Cash5.48

Book Value$2.29 per share

Price / Book7.57

Profitability

EPS (Most Recent Fiscal Year)$2.94

Net Income$6.58 million

Net Margins-379.64%

Return on Equity-574.62%

Return on Assets-203.65%

Miscellaneous

Employees11

Outstanding Shares2,590,000

Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals (NASDAQ:OPNT) announced its quarterly earnings data on Monday, December, 4th. The technology company reported ($2.77) EPS for the quarter, missing the Zacks' consensus estimate of ($1.19) by $1.58. The technology company had revenue of $0.02 million for the quarter. Opiant Pharmaceuticals had a negative net margin of 379.64% and a negative return on equity of 574.62%. View Opiant Pharmaceuticals' Earnings History.

Who are some of Opiant Pharmaceuticals' key competitors?

Some companies that are related to Opiant Pharmaceuticals include Amerigo Resources (ARREF), Wealth Minerals (WMLLF), Jaguar Mining (JAGGF), Rubicon Minerals (RBYCF), Bunker Hill Mining (BHLL), Alderon Iron Ore (AXXDF), Trident Brands (TDNT), Santa Fe Gold (SFEG), Silver Bull Resources (SVBL), Uranium Resources (WWR), Avalon Rare Metals (AVLNF), Atlatsa Resources (ATLRF), Quantum Materials (QTMM), Endurance Exploration Gr (EXPL) and Quaterra Resources (QTRRF).

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the folowing people:

Dr. Roger Crystal M.D., CEO, Pres & Director (Age 42)
Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 48)
Mr. David D. O'Toole, CFO, Treasurer & Sec. (Age 59)
Dr. Phil Skolnick Ph.D., D.Sc. (hon), Chief Scientific Officer (Age 71)
Mr. Quan Vu, VP of Corp. Devel.

Has Opiant Pharmaceuticals been receiving favorable news coverage?

News articles about OPNT stock have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also assigned headlines about the technology company an impact score of 46.58 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Opiant Pharmaceuticals' major shareholders?

Opiant Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Spark Investment Management LLC (0.39%). Company insiders that own Opiant Pharmaceuticals stock include David D O'toole, Geoffrey Wolf, Kevin Pollack, Michael Sinclair, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals.

Which major investors are selling Opiant Pharmaceuticals stock?

OPNT stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Geoffrey Wolf and Thomas T Thomas. View Insider Buying and Selling for Opiant Pharmaceuticals.

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $17.34.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $45.14 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $2.94 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 201 SANTA MONICA BOULEVARD SUITE 500, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]

MarketBeat Community Rating for Opiant Pharmaceuticals (OPNT)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		131 (Vote Outperform)
Underperform Votes:		143 (Vote Underperform)
Total Votes:		274

MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Opiant Pharmaceuticals (NASDAQ:OPNT) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details

(Data available from 5/23/2016 forward)

Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings History and Estimates Chart

Earnings by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings Estimates

2018 EPS Consensus Estimate: ($4.56)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($1.19)	($1.19)	($1.19)
Q2 2018	1	($1.26)	($1.26)	($1.26)
Q3 2018	1	($1.11)	($1.11)	($1.11)
Q4 2018	1	($1.00)	($1.00)	($1.00)

Opiant Pharmaceuticals (NASDAQ OPNT) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
12/4/2017	Q1 2018	($1.19)	($2.77)		$0.02 million	View	N/A
10/13/2017	Q4 2017	($0.87)	($0.17)		$3.77 million	View	N/A
6/14/2017	Q3 2017	($0.82)	($1.55)		$0.02 million	View	N/A
3/16/2017	Q2 2017	($0.85)	$4.91		$13.54 million	View	N/A
12/16/2016	Q1 2017	($1.14)	($0.30)	$0.70 million	$1.12 million	View	N/A
10/31/2016	Q4 2016		($0.52)	$0.10 million	$0.31 million	View	N/A
6/8/2016	Q3 2016		$0.15		$2.61 million	View	N/A
3/15/2016	Q2 2016		$1.52		$6.86 million	View	N/A
8/7/2012		$0.19	$0.21			View	N/A
5/14/2012		$0.20	$0.21			View	N/A
2/7/2012		$0.29	$0.26			View	N/A
11/9/2011		$0.24	$0.24			View	N/A
8/2/2011		$0.15	$0.21			View	N/A
5/9/2011		$0.19	$0.20			View	N/A
1/27/2011		$0.16	$0.23			View	N/A

(Earnings results data provided by Zacks Investment Research)

Opiant Pharmaceuticals (NASDAQ:OPNT) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Opiant Pharmaceuticals (NASDAQ OPNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 37.92%
Institutional Ownership Percentage: 4.34%

Insider Trading History for Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals (NASDAQ OPNT) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/18/2018	Thomas T Thomas	Director	Sell	2,763	$16.44	$45,423.72
5/16/2018	David D O'toole	CFO	Buy	2,000	$16.95	$33,900.00
5/15/2018	Thomas T Thomas	Director	Sell	4,300	$18.35	$78,905.00
5/11/2018	David D O'toole	CFO	Buy	3,000	$18.85	$56,550.00
12/18/2017	Geoffrey Wolf	Major Shareholder	Sell	34,938	$22.67	$792,044.46
12/8/2017	Geoffrey Wolf	Major Shareholder	Sell	2,570	$30.40	$78,128.00
1/17/2017	Michael Sinclair	Insider	Buy	3,500	$7.01	$24,535.00	132,720
1/17/2017	Roger Crystal	CEO	Buy	3,475	$6.99	$24,290.25	8,475
1/13/2017	Kevin Pollack	Insider	Buy	4,820	$6.98	$33,643.60	4,820

(Data available from 1/1/2013 forward)

Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines

Source:

Date	Headline
	Thomas T. Thomas Sells 2,763 Shares of Opiant Pharmaceuticals (OPNT) Stock www.americanbankingnews.com - May 18 at 8:35 PM
	Opiant Pharmaceuticals (OPNT) versus Nornickel (NILSY) Head to Head Contrast www.americanbankingnews.com - May 18 at 5:31 PM
	Q2 2018 Earnings Estimate for Opiant Pharmaceuticals Issued By Zacks Investment Research (OPNT) www.americanbankingnews.com - May 17 at 6:45 AM
	Insider Buying: Opiant Pharmaceuticals (OPNT) CFO Buys 2,000 Shares of Stock www.americanbankingnews.com - May 16 at 8:52 PM
	Opiant Pharmaceuticals (OPNT) Director Thomas T. Thomas Sells 4,300 Shares www.americanbankingnews.com - May 15 at 8:16 PM
	OPNT: KOL Event Highlights Medications for Addictions and Related Disorders finance.yahoo.com - May 15 at 5:41 PM
	Insider Buying: Opiant Pharmaceuticals (OPNT) CFO Buys 3,000 Shares of Stock www.americanbankingnews.com - May 14 at 4:33 PM
	Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update finance.yahoo.com - May 8 at 5:28 PM
	Head to Head Comparison: Opiant Pharmaceuticals (OPNT) vs. Uranium Resources (WWR) www.americanbankingnews.com - May 6 at 11:31 AM
	Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders finance.yahoo.com - May 3 at 8:26 AM
	Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose finance.yahoo.com - April 20 at 8:36 AM
	Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for ... globenewswire.com - April 19 at 8:26 AM
	BRIEF-Opiant Pharmaceuticals Awarded Grant Of Approximately $7.4 Mln From The National Institutes Of Health www.reuters.com - April 19 at 8:26 AM
	Opiant awarded $7.4M NIH grant to support OPNT003 development; shares ahead 2% premarket seekingalpha.com - April 18 at 5:37 PM
	Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose finance.yahoo.com - April 18 at 8:26 AM
	Will Opiant Pharma Solve The Biggest Crisis That The FDA Is Currently Facing? seekingalpha.com - April 11 at 8:42 AM
	ValuEngine Upgrades Opiant Pharmaceuticals (OPNT) to Strong-Buy www.americanbankingnews.com - April 9 at 11:35 AM
	Opiant Pharmaceuticals (OPNT) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 8 at 11:17 AM
	Opiant Pharmaceuticals (OPNT) Lifted to B at TheStreet www.americanbankingnews.com - April 6 at 4:46 PM
	Opiant Pharmaceuticals (OPNT) Lifted to "Hold" at ValuEngine www.americanbankingnews.com - April 5 at 1:11 PM
	ValuEngine Lowers Opiant Pharmaceuticals (OPNT) to Buy www.americanbankingnews.com - April 4 at 5:19 PM
	Zacks: Brokerages Anticipate Opiant Pharmaceuticals Inc (OPNT) to Post -$0.29 Earnings Per Share www.americanbankingnews.com - April 4 at 1:22 PM
	Free Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ Estimates finance.yahoo.com - March 22 at 8:38 AM
	Trump says he is working to lower prescription drug prices finance.yahoo.com - March 20 at 8:40 AM
	As U.S. opioid crisis grows, Trump calls for death penalty for dealers finance.yahoo.com - March 20 at 8:40 AM
	OPNT: Opiant Developing New Opioid Overdose Treatment finance.yahoo.com - March 19 at 5:10 PM
	Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference finance.yahoo.com - March 19 at 5:10 PM
	Kadmon (KDMN) & Opiant Pharmaceuticals (OPNT) Critical Analysis www.americanbankingnews.com - March 12 at 10:27 AM
	Opiant Pharmaceuticals (OPNT) and Syros Pharmaceuticals (SYRS) Critical Review www.americanbankingnews.com - March 10 at 12:17 PM
	Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides ... - GlobeNewswire (press release) globenewswire.com - March 9 at 8:35 AM
	Opiant Pharmaceuticals reports 5M results seekingalpha.com - March 7 at 6:23 PM
	Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update finance.yahoo.com - March 7 at 6:23 PM
	Opiant Pharmaceuticals (OPNT) to Release Earnings on Wednesday www.americanbankingnews.com - March 7 at 1:50 AM
	Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications - GlobeNewswire (press release) globenewswire.com - February 22 at 8:30 AM
	Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications finance.yahoo.com - February 22 at 8:30 AM
	Q2 2018 EPS Estimates for Opiant Pharmaceuticals Inc Lifted by Analyst (OPNT) www.americanbankingnews.com - February 15 at 10:18 AM
	OPNT: Developing Longer-Acting Opioid Overdose Treatment finance.yahoo.com - February 13 at 3:50 PM
	Opnet Technologies, Inc. (OPNT) Reports ~$11.7M in Royalty & Milestone Payments Related to 2017 Sales of NARCAN www.streetinsider.com - February 9 at 9:48 AM
	Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 ... - GlobeNewswire (press release) globenewswire.com - February 8 at 8:18 AM
	Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose finance.yahoo.com - February 8 at 8:18 AM
	Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants - GlobeNewswire (press release) globenewswire.com - January 2 at 5:35 PM
	Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants finance.yahoo.com - January 2 at 5:35 PM
	Insider Q&A: Narcan exec talks merits of spray for overdoses marketbeat.com - December 31 at 8:25 AM
	Critical Contrast: BioMarin Pharmaceutical (BMRN) vs. Opiant Pharmaceuticals (OPNT) www.americanbankingnews.com - December 27 at 10:00 AM
	ValuEngine Lowers Opiant Pharmaceuticals (OPNT) to Sell www.americanbankingnews.com - December 23 at 4:14 PM
	BioMarin Pharmaceutical (BMRN) versus Opiant Pharmaceuticals (OPNT) Head-To-Head Survey www.americanbankingnews.com - December 22 at 11:22 PM
	Zacks Investment Research Brokers Raise Earnings Estimates for Opiant Pharmaceuticals Inc (OPNT) www.americanbankingnews.com - December 22 at 1:26 PM
	FY2018 Earnings Forecast for Opiant Pharmaceuticals Inc Issued By Zacks Investment Research (OPNT) www.americanbankingnews.com - December 21 at 5:50 PM
	Geoffrey Wolf Sells 34,938 Shares of Opiant Pharmaceuticals Inc (OPNT) Stock www.americanbankingnews.com - December 21 at 2:18 PM
	OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18 finance.yahoo.com - December 20 at 4:40 PM

Opiant Pharmaceuticals (NASDAQ:OPNT) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Opiant Pharmaceuticals (NASDAQ:OPNT) Income Statement, Balance Sheet and Cash Flow Statement

Opiant Pharmaceuticals (NASDAQ OPNT) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff